Efficacy of luteinizing hormone activity in patients undergoing in vitro fertilization and treated only with low-dose recombinant choriogonadotropin alfa (Ovidrel) in the late follicular phase.
Ten good prognosis patients underwent IVF with a new ovarian stimulation protocol using only 8 microg of recombinant choriogonadotropin and a GnRH antagonist starting at a 14-mm lead follicle. Six of the 10 subjects delivered and all had supernumerary embryos for cryopreservation.
Kenigsberg
Daniel
D
Department of Obstetrics, Gynecology and Reproductive Medicine, SUNY, Stony Brook School of Medicine, Stony Brook, New York, USA. drkenigsberg@longislandivf.com
Madankumar
Rajeevi
R
Moodie
Glenn
G
Brenner
Steven H
SH
D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005307:Fertilization in Vitro / Q000187:drug effects* / Q000379:methods*; D005498:Follicular Phase / Q000097:blood* / Q000187:drug effects; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
D006063:Chorionic Gonadotropin; C412828:Ovidrel; D011994:Recombinant Proteins; D007986:Luteinizing Hormone